Now I have a clear picture. Let me finalize my review and score.

**Round 1 bracket**: Between 5.5 and 7.5. ProteinVista is clearly stronger than the 5.67-5.75 anchors (better controlled experiments, stronger SOTA claims, more thorough ablations) but doesn't reach the 8.0 papers (more novel methods, broader impact).

**Round 2 narrowing**: Comparing against AtomSurf (6.75) and the Bioactivity Prediction paper (7.00):
- ProteinVista has stronger practical impact than AtomSurf (compute efficiency is compelling) and better controlled baselines, but AtomSurf has more novel architectural contribution.
- The Bioactivity Prediction paper (7.00) introduces a new paradigm; ProteinVista is more incremental in methodology but has very strong empirical execution.

**Final assessment**: ProteinVista sits around **6.5** — above the 5.67-5.75 anchors due to superior experimental methodology, honest evaluation, and compelling compute efficiency claims; slightly below AtomSurf (6.75) because the 3D-CNN-on-voxels approach itself isn't novel, the missing graph-based baselines are a gap, and the ensemble comparison has confounds.

Here is the full consolidated review:

---

## Summary
ProteinVista introduces a compute-efficient full-atom 3D CNN (123M parameters) pre-trained on ~500K AlphaFold-2 structures via contrastive learning against ESM-2 embeddings. It outperforms or matches ESM-2 sequence transformers on protein-ligand prediction benchmarks (transporter-substrate, enzyme-substrate classification, IC₅₀ regression) while using ~1% of the pre-training GPU-hours of ESM-2_650M, and demonstrates complementary value when ensembled with ESM-2 on classification tasks.

## Strengths
- **Well-controlled experimental setup isolates protein encoder contribution**: All models use identical prediction heads, identical MolFormer small-molecule embeddings, and the same hyperparameter search procedure (Section 3.1, lines 87–96). This credibly isolates the effect of protein encoder choice rather than conflating it with downstream architecture differences.
- **Honest evaluation including negative results**: The GO annotation result showing ProteinVista underperforming ESM-2 (Fmax 0.57 vs. 0.62, Section 3.4, line 150) and the IC₅₀ ensemble degradation (R² drops from 0.69 to 0.68, Table 2) are reported straightforwardly, strengthening credibility. The storage cost trade-off (75 GB vs. 3 MB, line 194) is also quantified honestly.
- **Statistical significance testing accompanies all key claims**: McNemar's tests for classification (p < 10⁻¹³ for TSP, p < 10⁻¹⁷ for ESP, line 117) and Wilcoxon signed-rank test for regression (p < 10⁻³⁰⁴ for IC₅₀, lines 119–120) provide rigorous evidence.
- **Informative ablations dissecting key design choices**: Section 4.2 systematically varies test-time views, training augmentation, pre-training objective, and voxel resolution, revealing that single-view inference degrades R² by 6.4% while training augmentation removal has no effect (−0.1%) (lines 164–170).
- **Substantial compute efficiency**: Pre-training on 4 A100 GPUs for 48 hours vs. 128 H100 GPUs for ~7 days (~1% GPU-hours), with faster inference (20s vs. 426s per 1K proteins on one A100) (Section 4.3, lines 172–194).
- **Nuanced analysis of when structure vs. sequence information helps**: Stratification by sequence identity, TM-score, and pLDDT (Section 4.1, lines 156–162) reveals ProteinVista excels when test proteins share high identity/structure with training and when AlphaFold-2 structures are high-confidence (pLDDT > 90).

## Weaknesses

### Fatal
None.

### Major
- **Ensemble comparison lacks a two-ESM-2-model control**: The ESM-ProteinVista ensemble is compared only against single ESM-2 models (Tables 1–2). Ensembling two diverse models inherently gains from model diversity alone, not just complementarity of information type. Comparing against an ESM-2₁₅₀M + ESM-2₆₅₀M ensemble would isolate whether the gains come from structural information or merely from combining two different models. This matters for the complementarity claim made on lines 117 and 160. Note: the single-model comparisons (ProteinVista alone vs. ESM-2 alone) are fair and do support the core claim — the concern applies specifically to the complementarity/enhancement claims.

- **No direct comparison with graph-based structure methods despite introduction's sustained argument against them**: The introduction devotes significant space arguing that graph-based methods (DeepFRI, GearNet, ESM-GearNet) are insufficient because they lack atom-level detail (lines 17–23), yet the experiments compare only against sequence-only ESM-2 and task-specific SOTA. A direct comparison against ESM-GearNet on at least one benchmark would close the gap between the motivating argument and the evidence. The paper notes that the ESM-GearNet study showed these methods only marginally outperform ESM-2 (line 23), but a direct empirical comparison would be far more convincing than citing secondhand results.

### Minor
- **Rotation robustness is overstated in the abstract and introduction**: The abstract claims "rotation-robust representations through 3D data augmentation" (line 9) and the figure caption states "To enforce rotational invariance" (line 49). However, the ablation in Section 4.2 shows that removing training-time augmentation has virtually no effect (−0.1% R²) while reducing from 5 to 1 test-time views drops performance by 6.4% (line 168). This indicates the model is NOT rotation-robust in its learned representations — it relies on averaging multiple augmented views at inference time. The paper should be clearer that this is test-time ensembling over discrete orientations, not learned rotation invariance.

- **Optimized pipeline (Section 3.3) conflates ProteinVista-specific gains with pipeline improvements**: ESM-ProteinVista_OP uses fine-tuned MolFormer, contrastive networks, and prediction averaging (line 138), a substantially more complex pipeline than the base comparison. The gains over SOTA methods cannot be cleanly attributed to ProteinVista's representations alone. The paper should either show that the same pipeline improvements also substantially benefit ESM-2 alone, or more clearly delineate which gains come from ProteinVista versus the pipeline optimization.

### Trivial
None.

## Nice-to-Haves
- Report variance or confidence intervals across random seeds for key fine-tuning experiments.
- Discuss practical solutions for the storage cost challenge (75 GB vs. 3 MB per ~5,800 proteins, line 194), such as compressed representations, on-the-fly structure prediction with ESMFold, or caching strategies.

## Removed Points
These points are flagged to be removed, treat them with caution:
- Density formula appears garbled (line 57, "$\vec{v} = \exp(-\|\vec{v} - \vec{r}\|/\sigma^2)$" uses v⃗ on both sides): This is a parser artifact, not a paper error.
- Extreme p-values (10⁻³⁰⁴) driven by large test set size: Standard reporting practice, not a real weakness.
- ESP result framing: The paper actually says "surpasses or equals" (line 115), which is accurate for the tie at 91.8% vs. 91.9%.
- Missing related works: Cannot verify existence of claimed missing works.
- Reproducibility nitpicks about undisclosed hyperparameters: Not substantive for a method paper of this type.

## Novel Insights
The key insight from synthesizing the reviews is that ProteinVista's contribution is not just a new model but a convincing demonstration that full-atom 3D CNNs are now tractable at scale — countering the prevailing assumption (explicitly cited in line 29) that they are computationally prohibitive. The ablation revealing that training-time augmentation has no effect while test-time view averaging is critical (Section 4.2) suggests the model learns orientation-dependent features during pre-training that are then averaged out at inference, raising an architectural question about whether equivariant 3D CNNs would be more principled. The honest negative result on GO annotation (Section 3.4) provides a useful boundary condition for when atom-level structure information is and is not beneficial.

## Suggestions
- Add a two-ESM-2-ensemble control experiment to strengthen the complementarity claim.
- Include at least one direct comparison against ESM-GearNet or a similar graph-based method on TSP or ESP.
- Reframe the rotation discussion to explicitly acknowledge test-time ensembling vs. true invariance, and discuss as a future direction whether SE(3)-equivariant architectures would be more principled.
- For the optimized pipeline (Section 3.3), apply the same pipeline improvements to ESM-2 alone and report the result to disentangle pipeline gains from encoder gains.

---

## Calibration Report

**Round 1 anchors:**
- Weak band: rEQ8OiBxbZ (3.00, round 1) — rejected 3D molecular pretraining paper; ProteinVista is much stronger. jqx5XI4Yr3 (3.40, round 1) — rejected ProteinAdapter; ProteinVista has better experiments and results.
- Middle band: BEH4mGo7zP (5.75, round 1) — ProteinINR, accepted; marginal improvements over existing work, weaker evaluation than ProteinVista. sTYuRVrdK3 (6.25, round 1) — ProteinWorkshop benchmark; different contribution type but comparable quality. AXbN2qMNiW (5.67, round 1) — protein-ligand binding representation; weaker controls and smaller scope than ProteinVista.
- Strong band: 0ctvBgKFgc (8.00, round 1) — ProtComposer; significantly more novel method with broader impact. kJFIH23hXb (8.00, round 1) — FoldFlow; more theoretically grounded and novel.

**Round 2 anchors:**
- S8gbnkCgxZ (7.00, round 2) — Bioactivity Prediction redefinition; introduces new paradigm/dataset, stronger novelty than ProteinVista's more incremental method. ProteinVista is below this.
- ARQIJXFcTH (6.75, round 2) — AtomSurf; surface+graph hybrid achieving SOTA on Atom3D. Comparable quality but more novel architecture. ProteinVista is slightly below.
- RgE1qiO2ek (6.25, round 2) — 3DMolFormer; dual-channel transformer for docking. ProteinVista has better controlled comparisons and compute efficiency story. ProteinVista is slightly above.
- RyWypcIMiE (6.50, round 2) — SBDD evaluation framework; different contribution type but similar impact level.

**Bracket**: Round 1 placed the paper between 5.5 and 7.5. Round 2 narrowed this to between 6.0 and 7.0. The paper is above the 5.67–5.75 anchors (better controlled, stronger SOTA claims, compute efficiency) and below the 6.75–7.00 anchors (less novel method, missing graph-based baselines). The final score of 6.5 places it squarely in the middle of the Round 2 band, comparable to 3DMolFormer (6.25) and slightly below AtomSurf (6.75).

MY FINAL SCORE: <score>6.5</score>
MY FINAL DECISION: <decision>Accept</decision>